Effect of Daptomycin on Local Interleukin-6, Matrix Metalloproteinase-9, and Metallopeptidase Inhibitor 1 in Patients With MRSA-Infected Diabetic Foot

被引:11
作者
Ambrosch, Andreas [1 ,2 ]
Halevy, Daniel [3 ]
Fwity, Boushra [2 ]
Brin, Thomas [2 ]
Lobmann, Ralf [3 ]
机构
[1] Hosp Barmherzige Bruder, Inst Lab Med Microbiol & Hyg, Regensburg, Germany
[2] St Joseph Hosp, Inst Lab Med & Microbiol, Bremerhaven, Germany
[3] Stuttgart Burgerhosp, Dept Endocrinol Diabetol & Geriatr, Stuttgart, Germany
关键词
MRSA; MMP-9; diabetic foot; TIMP-1; daptomycin; RESISTANT STAPHYLOCOCCUS-AUREUS; COMPLICATED SKIN; RISK-FACTORS; VANCOMYCIN; EXPRESSION; ULCERS; TRIAL;
D O I
10.1177/1534734614523126
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
Infection is a major cause of the diabetic foot syndrome that is promoted by the increased burden of multiresistant germs like methicillin-resistant Staphylococcus aureus (MRSA). Maximizing positive outcome for serious MRSA infections requires an aggressive treatment approach and careful monitoring of the healing process. Therefore, we examined 8 patients with MRSA-infected diabetic foot syndrome of Wagner classification grade 2 or 3 (corresponding to the Texas classification stage 2 or 3) during antibiotic treatment with daptomycin. We documented the wound size and obtained samples of wound secretion for analyses of proinflammatory interleukin-6 (IL-6), protease (matrix metalloproteinase-9 [MMP-9]), and antiprotease (metallopeptidase inhibitor 1 [TIMP-1]) activity. During the course of anti-MRSA therapy, we observed a decrease in the concentration of local IL-6 within the first 3 days followed by a decrease of MMP-9 and an increase of TIMP-1. Finally, a reduction of wound size was documented. The present data show that efficient antimicrobial treatment with daptomycin has a number of beneficial effects on wound healing at the molecular level in MRSA-infected diabetic foot ulcers.
引用
收藏
页码:12 / 16
页数:5
相关论文
共 28 条
[1]
Interleukin-6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation [J].
Ambrosch, Andreas ;
Lobmann, Ralf ;
Pott, Andreas ;
Preissler, Jurgen .
INTERNATIONAL WOUND JOURNAL, 2008, 5 (01) :99-106
[2]
[Anonymous], OFF STAND WOUND INF
[3]
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[4]
Gelatinase concentration in tears of corneal-grafted patients [J].
Barro, CD ;
Romanet, JP ;
Fdili, A ;
Guillot, M ;
Morel, F .
CURRENT EYE RESEARCH, 1998, 17 (02) :174-182
[5]
Wound healing and its impairment in the diabetic foot [J].
Falanga, V .
LANCET, 2005, 366 (9498) :1736-1743
[6]
In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants [J].
Fluit, AC ;
Schmitz, FJ ;
Verhoef, J ;
Milatovic, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1007-1011
[7]
Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin [J].
French, G. L. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (06) :1107-1117
[8]
Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis [J].
Kessler, L ;
Piemont, Y ;
Ortega, F ;
Lesens, O ;
Boeri, C ;
Averous, C ;
Meyer, R ;
Hansmann, Y ;
Christmann, D ;
Gaudias, J ;
Pinget, M .
DIABETIC MEDICINE, 2006, 23 (01) :99-102
[9]
Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost [J].
Lipsky, B. A. ;
Tabak, Y. P. ;
Johannes, R. S. ;
Vo, L. ;
Hyde, L. ;
Weigelt, J. A. .
DIABETOLOGIA, 2010, 53 (05) :914-923
[10]
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections [J].
Lipsky, BA ;
Stoutenburgh, U .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (02) :240-245